Aripiprazole Dosing for OCD
Aripiprazole should be used as augmentation therapy (not monotherapy) for treatment-resistant OCD at a dose of 10-15 mg/day, added to an ongoing SSRI or clomipramine regimen. 1
Clinical Context and Evidence Base
Aripiprazole is not a first-line treatment for OCD. The 2019 Nature Reviews Disease Primers guidelines clearly establish that SSRIs are first-line pharmacotherapy, and aripiprazole enters the picture only when patients fail to respond adequately to SSRI monotherapy 1. Meta-analytic evidence supports efficacy for both risperidone and aripiprazole augmentation in SSRI-resistant OCD, though the effect size is modest—only about one-third of treatment-resistant patients show clinically meaningful response 1.
Specific Dosing Algorithm
Starting Dose
- Begin at 5-10 mg/day added to the existing SSRI/clomipramine regimen 2, 3
- The most robust double-blind RCT used 15 mg/day as the standard augmentation dose 2
Titration Strategy
- Start at 5 mg/day if concerned about tolerability
- Titrate to 10-15 mg/day over 1-2 weeks
- Maximum dose: 20 mg/day (though doses above 15 mg rarely provide additional benefit) 3, 4
- Mean effective dose in clinical studies: 10.9-12.6 mg/day 3, 4
Duration of Trial
- Assess response at 4 weeks to determine if continuation is warranted 5
- Full trial duration should be 12-16 weeks before declaring treatment failure 2, 3
Critical Safety Considerations
Monitor closely for metabolic adverse effects including weight gain and metabolic dysregulation, which are the primary concerns with antipsychotic augmentation 1. The most common side effects requiring monitoring include:
- Akathisia (most common reason for early discontinuation) 6, 3
- Weight gain (mean 1.8 kg in studies) 6
- Nausea/vomiting
- Tremor and inner restlessness 3
Important caveat: Approximately 21% of patients discontinue due to adverse effects 7, so ongoing risk-benefit assessment is essential.
Comparison to FDA Labeling
The FDA label for aripiprazole 8 does not include OCD as an approved indication—it covers schizophrenia, bipolar disorder, and other conditions. The doses mentioned (10-30 mg/day for schizophrenia) are higher than what evidence supports for OCD augmentation. This represents off-label use supported by guideline recommendations and research evidence.
When to Consider Aripiprazole
Use aripiprazole augmentation when:
- Patient has failed adequate SSRI trial (8-12 weeks at therapeutic dose) 1
- CBT is unavailable, not tolerated, or has failed 1
- Patient cannot tolerate or has failed clomipramine augmentation (which has stronger efficacy data but higher risk of serious adverse events including seizures and cardiac arrhythmias) 1
Practical Clinical Pearls
Lower doses may be more effective and better tolerated than higher ones in some patients 7. If a patient experiences significant side effects at 15 mg/day, consider reducing to 5-10 mg/day rather than discontinuing entirely, as clinical experience suggests doses beyond 5 mg are not always necessary for efficacy 7.
Response pattern: When effective, improvement typically appears within 30 days of starting aripiprazole and symptoms may return within 30 days of discontinuation 9. This relatively rapid onset can help guide decision-making about continuation.
The strongest evidence comes from a 2011 double-blind RCT showing significant improvement in Yale-Brown Obsessive Compulsive Scale scores with 15 mg/day aripiprazole augmentation (P < 0.0001 for total score) 2, and this is corroborated by multiple open-label studies and a 2014 meta-analysis 5.